A 58-year-old man with COPD GOLD Stage II (FEV₁ 50–79% predicted) presents with persistent dyspnea on exertion despite smoking cessation. He has no features of asthma overlap. What is the drug of choice for maintenance therapy?

Explanation

## COPD Maintenance Therapy Selection **Key Point:** For COPD GOLD Stage II (moderate airflow limitation) without asthma features, a single long-acting bronchodilator is first-line. LAMA is preferred over LABA as monotherapy because it provides superior symptom control and exacerbation reduction in pure COPD. ### GOLD 2023 Recommendation LAMA monotherapy is recommended for: - Patients with ≥1 moderate exacerbation in the past year, OR - Persistent symptoms despite smoking cessation LABA monotherapy is an alternative but is less effective than LAMA in reducing exacerbations in COPD-only patients (without asthma). ### Why LAMA > LABA in COPD? | Feature | LAMA | LABA | |---------|------|------| | Exacerbation reduction | Superior | Moderate | | Symptom control | Excellent | Good | | Mortality benefit | Demonstrated | Not shown | | Asthma overlap risk | Safe | Relative contraindication | **High-Yield:** LAMA agents (tiotropium, glycopyrronium, umeclidinium) are the preferred single-agent bronchodilator for COPD without asthma. They reduce exacerbations by ~25% and improve FEV₁ more than LABA monotherapy. **Clinical Pearl:** If the patient had asthma-COPD overlap (ACO), LABA would be preferred because LAMAs are less effective in asthma. However, pure COPD = LAMA first. **Mnemonic:** LAMA = **L**ong-acting **M**uscarinic **A**ntagonist = **A**ntagonizes **A**cetylcholine (parasympathetic) = Bronchodilation + reduced mucus + reduced exacerbations. ## Why Other Options Are Wrong - **LABA monotherapy:** Second-line alternative; inferior to LAMA for exacerbation prevention in COPD without asthma. - **ICS monotherapy:** Contraindicated as monotherapy in COPD; increases pneumonia risk without mortality benefit. Reserved for asthma-COPD overlap or frequent exacerbators (≥2/year) on dual bronchodilators. - **Theophylline:** Obsolete; narrow therapeutic index, poor tolerability, and inferior efficacy compared to modern bronchodilators.